EP
TVTX icon

Eversept Partners’s Travere Therapeutics TVTX Stock Holding History

Eversept Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.1M Sell
542,610
-632,358
-54% -$18.9M 0.85% 29
2025
Q4 		$44.9M Sell
1,174,968
-242,236
-17% -$7.88M 2.26% 10
2025
Q3 		$33.9M Buy
1,417,204
+102,171
+8% +$1.92M 2.33% 15
2025
Q2 		$19.5M Buy
1,315,033
+498,779
+61% +$8.27M 1.79% 17
2025
Q1 		$14.6M Buy
816,254
+325,958
+66% +$6.62M 1.49% 25
2024
Q4 		$8.54M Sell
490,296
-379,617
-44% -$6.71M 0.76% 27
2024
Q3 		$12.2M Sell
869,913
-221,252
-20% -$2.31M 0.83% 25
2024
Q2 		$8.97M Buy
1,091,165
+135,547
+14% +$913K 0.61% 30
2024
Q1 		$7.37M Buy
+955,618
New +$8.06M 0.49% 38

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Eversept Partners's TVTX Position: Q1 2026 in Review

Eversept Partners reduced its Travere Therapeutics (TVTX) stake by 54% in Q1 2026, selling an estimated $18.9M and leaving 542,610 shares worth $16.1M. The position accounts for 0.85% of the portfolio, ranked #29.

Eversept Partners first reported a position in TVTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $44.9M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Eversept Partners held 542,610 shares of Travere Therapeutics worth $16.1M as of Q1 2026.
  • Eversept Partners sold 632,358 Travere Therapeutics shares in Q1 2026, an estimated $18.9M.
  • Travere Therapeutics made up 0.85% of Eversept Partners's portfolio in Q1 2026, its #29 holding.
  • Eversept Partners first reported a position in Travere Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Eversept Partners's Travere Therapeutics position peaked at $44.9M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.